OBJECTIVE AND DESIGN: The resistance of @entity2013 to @entity935 agonist (DA) therapy, whether defined as an absence of PRL normalization or the lack of significant @entity5 shrinkage after prolonged treatment at high doses, is usually regarded as unpredictable. The aim of this retrospective study, conducted in a teaching hospital, was to determine whether cavernous sinus (CS) invasion assessed by magnetic resonance imaging (MRI) is associated with a higher rate of resistance to DA therapy. METHODS: Forty-nine @entity1 with a @entity2013 were included in this study and classified into four groups according to the percentage of encasement of the intracavernous internal carotid artery (ICA) by the @entity5 . All @entity1 received DA as the primary treatment, mainly @entity9229 ( @entity14137 ). PRL normalization and @entity5 shrinkage during treatment were evaluated as a function of CS invasion. RESULTS: @entity5 encasing more than three-quarters of the intracavernous @entity6455 (group 4) were less responsive to DA therapy, exhibiting a lower rate of early (< or = 3 months) PRL normalization (8%vs. 69% in the others groups; P < 0.01) under a higher dose of @entity14137 (median: 3.5 mg vs. 1.0 mg per week; P < 0.01). CS invasion was a strongly significant and independent predictor of hormonal resistance to @entity14137 (P < 0.01). This hormonal resistance occurred in eight @entity1 (16%), all but one belonging to group 4. Significant @entity5 shrinkage was observed in 31 out of 45 assessable cases (69%) and was more likely to occur in the case of PRL normalization (P < 0.01). CONCLUSIONS: Parasellar extension of @entity2013 , assessed on the basis of strict MRI criteria, may predict a negative response to DA. The @entity2013 (over 90%) is similar to that reported in @entity2013 , whereas invasive @entity5 are resistant to treatment in more than 50% of cases.

Influence of parasellar extension of XXXX defined by magnetic resonance imaging on their responsiveness to @entity935 agonist therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity14137 :: ('MESH:C014396', 'Chemical') :: ['CAB'] @entity2013 :: ('MESH:D015175', 'Disease') :: ['macroprolactinomas', 'microprolactinomas', 'macroprolactinoma', 'responsiveness of noninvasive macroprolactinomas'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['cabergoline'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumours', 'tumours', 'tumour'] @entity6455 :: ('CHEBI:29202', 'Chemical') :: ['ICA']
@entity2013 :: (MESH:D015175,Disease) :: ['macroprolactinomas']
